1. Home
  2. MXCT vs BMN Comparison

MXCT vs BMN Comparison

Compare MXCT & BMN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

HOLD

Current Price

$1.24

Market Cap

136.2M

Sector

Health Care

ML Signal

HOLD

Logo BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BMN

BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

HOLD

Current Price

$24.01

Market Cap

145.5M

Sector

Finance

ML Signal

HOLD

Company Overview

Basic Information
Metric
MXCT
BMN
Founded
1999
N/A
Country
United States
United States
Employees
N/A
19800
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Trusts Except Educational Religious and Charitable
Sector
Health Care
Finance
Exchange
Nasdaq
Nasdaq
Market Cap
136.2M
145.5M
IPO Year
2021
2020

Fundamental Metrics

Financial Performance
Metric
MXCT
BMN
Price
$1.24
$24.01
Analyst Decision
Buy
Analyst Count
4
0
Target Price
$5.50
N/A
AVG Volume (30 Days)
403.0K
12.2K
Earning Date
05-12-2026
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$33,026,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$18.50
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.64
$23.36
52 Week High
$1.86
$27.96

Technical Indicators

Market Signals
Indicator
MXCT
BMN
Relative Strength Index (RSI) 49.52 32.01
Support Level $1.19 N/A
Resistance Level $1.30 $26.20
Average True Range (ATR) 0.05 0.53
MACD -0.00 -0.16
Stochastic Oscillator 54.29 8.03

Price Performance

Historical Comparison
MXCT
BMN

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About BMN BlackRock 2037 Municipal Target Term Trust of Beneficial Interest

BlackRock 2037 Mun Tgt is a non-diversified, closed-end management investment company. The Trust's investment objective is to provide current income that is exempt from regular federal income tax. The Trust invests in investment grade quality securities or securities that are unrated but judged to be of comparable quality by the investment adviser.

Share on Social Networks: